Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Radiology Imaging | June 08, 2016

Why Developing Multiple Screening Technologies is a Must

MR

MR prostate image courtesy of Siemens Healthineers

Effective screening may be the key to America’s future. Only by catching disease early, before disease can injure the patient and impose financial penalties from lost work and medical expenses, can America achieve its dual goals of high-quality healthcare at low cost. Cancer, more than any other disease, exemplifies the promise and challenge.

Modern mammography screening may reduce deaths from breast cancer up to 28 percent. This success raises hope that similar gains might be made against other cancers. The use of computed tomography (CT) for lung screening and magnetic resonance imaging (MRI) for examining the prostate illustrate the two extremes of how this might be approached.

Low-dose CT lung screen has come in the wake of failed tests, namely chest X-rays and sputum cytology, neither of which has decreased lung cancer mortality. In contrast, prostate MRI is being pursued as one of several interlocking technologies and techniques that include digital exams performed by gloved physicians, PSA blood tests and ultrasound follow-up.

The latest MR advance is non-invasive, thanks to surface coils whose use streamlines patient set-up and accelerates scans. Adding to the future potential of prostate assessment are several positron emission tomography (PET) radiotracers that show promise for identifying prostate cancer, metastatic spread and relapse. Notably new opportunities are also arising in single-photon emission computerized tomography (SPECT) and PET/MR.

Although screening, diagnosis and monitoring for prostate cancer are still very far from perfect, they exemplify where screening needs to go.

 

Know When to Fold ‘Em

Rather than depending entirely on a single imaging technology, as does CT lung screening, or heavily so, as does mammography, prostate screening is part of a multi-pronged approach that may provide the flexibility for developers to adjust their R&D and for healthcare strategists to fine tune protocols.

The advantage stems from the cautionary tale of putting all your eggs in one basket. Spreading those eggs around provides options. Just as importantly, having multiple options could help developers know when to quit — when to walk away from a technology that has gone sour and pursue more promising ones.

All too often innovators, having fallen in love with a technology, doggedly pursue it, wasting huge sums of money in the process. In the case of screening, this could do an even greater harm, delaying the development of effective screening tools.

The irony, of course, is that money can limit the development of multiple technologies, leading entrepreneurs to gamble on a “best bet.” Funding can be particularly problematic for publicly held companies, which must account for expenditures to shareholders. This is where a silent partner can come in handy. And there are few in a better position to play this role than the Federal government.

Through innovation grants, the Feds scatter seed money like a tech-savvy Johnny Appleseed. Among the sources: the Federal Laboratory Consortium for Technology Transfer, Small Business Innovation Research, Small Business Technology Transfer and Experimental Program to Stimulate Competitive Research.

Those funds too are finite — and getting more so. But the argument for the Feds climbing onboard makes more sense than ever.

 

Turning to Uncle Sam

It goes like this. Value medicine has, at its core, an emphasis on prevention. As the population gets older, workers look to extend their livelihood (in fact, the economy, at least in the near term, is depending on it). The ability of healthcare to maintain worker viability will be essential. And it will have to be done cost-effectively. That means keeping a lid on medical expenses.

Better healthcare, improved quality of life, lower costs — it’s a challenging hat trick. And it can’t be done without disease prevention. And in that screening will be enormously important.

Medical imaging already has the core tool sets upon which to build. The current — and evolving — approach to prostate assessment shows where screening could go. CT lung screening will be a significant step in the same direction only if other technologies are brought in to complement it.

Screening is too important to America’s future to bet on single paths of technological development. We cannot simply wait for the right technology to plop serendipitously into our collective lap.

Editor's note: This is the second blog in a four-part series on screening. The first blog, “Screening: How New Looks at Old Modalities Might Turn Imaging Upside Down,” can be found here.


Related Content

News | Remote Viewing Systems

August 7, 2025 — DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc., announced it has received FDA 510(k) ...

Time August 07, 2025
arrow
Feature | X-Ray | By Siân Phillips, MD

Imaging is a crucial diagnostic, treatment and monitoring tool in modern medicine. From diagnosis to disease management ...

Time July 31, 2025
arrow
News | Digital Radiography (DR)

July 30, 2025 — Fujifilm Healthcare Americas Corp., a leading provider of diagnostic and enterprise imaging solutions ...

Time July 30, 2025
arrow
News | Advanced Visualization

July 28, 2025 — Frost & Sullivan has named Siemens Healthineers the 2025 North America Company of the Year in the ...

Time July 28, 2025
arrow
News | X-Ray

July 24, 2025 — GE HealthCare has announced the commercial availability of an advanced floor-mounted digital X-ray ...

Time July 24, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
News | Breast Imaging

QT Imaging Holdings, Inc. has announced the launch of its latest QTviewer, version 2.8. QTviewer stores and displays the ...

Time July 21, 2025
arrow
News | Artificial Intelligence

July 17, 2025 — HOPPR, a secure AI development platform for medical imaging, has announced the commercial release of its ...

Time July 17, 2025
arrow
News | Breast Imaging

July 17, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health ...

Time July 17, 2025
arrow
News | Focused Ultrasound Therapy

July 15, 2025 — Newswise —The UK Focused Ultrasound Foundation and Pancreatic Cancer UK have announced a new partnership ...

Time July 16, 2025
arrow
Subscribe Now